X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

CANCER IMMUNOLOGY IMMUNOTHERAPY

期刊標題檢索 CANCER IMMUNOL 最新評論: Where can I see how many reviewers have been invited, thank you (2024-05-16)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[CANCER IMMUNOLOGY IMMUNOTHERAPY]您好,您是該頁面的第 62781 位訪客。

期刊簡介
期刊名稱CANCER IMMUNOLOGY IMMUNOTHERAPY CANCER IMMUNOLOGY IMMUNOTHERAPY
LetPub Score
7.7
50 ratings
Rate

Reputation
8.8

Influence
6.5

Speed
8.9

期刊簡稱CANCER IMMUNOL IMMUN
ISSN0340-7004
E-ISSN1432-0851
h-index104
CiteScore
CiteScoreSJRSNIPCiteScore Rank
10.501.6630.962
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q153 / 404
Category: Medicine
Subcategory: Cancer Research
Q146 / 230
Category: Medicine
Subcategory: Immunology and Allergy
Q148 / 233
Category: Medicine
Subcategory: Immunology
Q150 / 236

自引率 (2023-2024)0.00%自引率趨勢
掲載範囲
Cancer Immunology, Immunotherapy has the basic aim of keeping readers informed of the latest research results in the fields of oncology and immunology. As knowledge expands, the scope of the journal has broadened to include more of the progress being made in the areas of biology concerned with biological response modifiers. This helps keep readers up to date on the latest advances in our understanding of tumor-host interactions.

The journal publishes short editorials including "position papers," general reviews, original articles, and short communications, providing a forum for the most current experimental and clinical advances in tumor immunology.
官方網站https://www.springer.com/262
在線稿件提交https://www.editorialmanager.com/ciim
開放訪問No
出版商Springer Berlin Heidelberg
主題領域医学
出版國/地區UNITED STATES
發行頻率月刊
創刊年1976
每年文章數207每年文章數趨勢
黃金OA百分比37.71%
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
IMMUNOLOGYSCIEQ256/181
ONCOLOGYSCIEQ176/322
索引 (SCI or SCIE)Science Citation Index
Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0340-7004%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Average 1 Month(s)
競爭力 *來自作者的數據: Moderate
參考鏈接
相關期刊 【CANCER IMMUNOLOGY IMMUNOTHERAPY】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    NATURE REVIEWS IMMUNOLOGYH-index: 351

    CiteScore: 93.40
    NATURE IMMUNOLOGYH-index: 344

    CiteScore: 40.00
    Annual Review of ImmunologyH-index: 279

    CiteScore: 57.20
    ImmunityH-index: 355

    CiteScore: 49.40
    Cellular & Molecular ImmunologyH-index: 64

    CiteScore: 31.20
    TRENDS IN IMMUNOLOGYH-index: 209

    CiteScore: 25.10
    JOURNAL OF EXPERIMENTAL MEDICINEH-index: 411

    CiteScore: 26.60
    AUTOIMMUNITY REVIEWSH-index: 103

    CiteScore: 24.70
    BRAIN BEHAVIOR AND IMMUNITYH-index: 127

    CiteScore: 29.60
    JOURNAL OF AUTOIMMUNITYH-index: 101

    CiteScore: 27.90
    學科內最受檢索的期刊 頁面查看次數
    International Immunopharmacology316288
    JOURNAL OF IMMUNOLOGY156690
    Immunity107936
    Cellular & Molecular Immunology107433
    Vaccine104772
    JOURNAL OF EXPERIMENTAL MEDICINE99452
    MICROBIAL PATHOGENESIS94242
    MOLECULAR IMMUNOLOGY91042
    INFLAMMATION89741
    BRAIN BEHAVIOR AND IMMUNITY84727
  •  

    CANCER IMMUNOLOGY IMMUNOTHERAPY CANCER IMMUNOLOGY IMMUNOTHERAPY
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    3    4    5    6    下一頁    末頁  (頁
/6)
  [CANCER IMMUNOLOGY IMMUNOTHERAPY] 的評論撰寫評論
作者: 四风碧芙


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-16 22:43:52 評論於
Where can I see how many reviewers have been invited, thank you
(0) 讚! | 四风碧芙

作者: 一条小友容


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-29 21:56:07 評論於
About how long does it take to receive the proof? It has been over a week and I have not received it yet
(0) 讚! | 一条小友容

作者: 雨巷少年印枝


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-01-10 22:58:20 評論於
Please translate the following paragraph into English and Japanese
(0) 讚! | 雨巷少年印枝

作者: 长文小哥哥


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-12-31 08:50:04 評論於
What's going on, how can a 6-point non-OA journal be listed in the third district, it's really outrageous
(0) 讚! | 长文小哥哥

作者: 天霜天罡


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-12-23 08:23:24 評論於
Review speed: 4.0 Emphasis on Research Direction: Immunology; Tumor Immunology Experience to Share: Achieved Tier 3, not cost-effective
(0) 讚! | 天霜天罡

作者: 般若沛旋


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-12-11 17:41:30 評論於
I haven't found the reviewer yet, once found it will be waiting for the reviewer's report
(0) 讚! | 般若沛旋

作者: Tracy Byron


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-12-09 15:14:37 評論於
Please translate the following paragraph into English and Japanese, and title them ":" and ":"
(0) 讚! | Tracy Byron

作者: 努力啊大雪绿


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-12-06 17:28:39 評論於
Hello, may I ask what the indication is when a review is in the reviewing status? Mine has been stuck at "31 reviewers invited" and I'm not sure if it's in review or if reviewers have not been found yet
(0) 讚! | 努力啊大雪绿

作者: 天霜天罡


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-25 09:11:46 評論於
Hello, have you received any news? I have been looking for a reviewer for three months, but I still haven't received any response to my emails
(0) 讚! | 天霜天罡

作者: 天霜天罡


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-22 21:34:17 評論於
Congratulations! I urge the editor, too slow
(0) 讚! | 天霜天罡

作者: 般若沛旋


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-19 15:10:00 評論於
My today has been officially received. You can write a reminder letter again. We wrote three times, and later they were all processed quickly
(0) 讚! | 般若沛旋

作者: 魔都代瑶


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-11 18:08:42 評論於
+1, I also don't have permission to access the interface
(0) 讚! | 魔都代瑶

作者: 朝阳超级甜


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-06 12:44:59 評論於
Review Speed: 6.0 | Acceptance Rate: 25.0
Sharing Experience: It took 4 months to find reviewers with no response at all, very slow, and don't know how to withdraw the submission
(0) 讚! | 朝阳超级甜

作者: 天霜天罡


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-02 19:44:20 評論於
11 Reviewer(s) invited for almost two months
(0) 讚! | 天霜天罡

作者: 访儿小可爱


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-24 17:57:23 評論於
Does anyone know why the submission page shows "you do not have sufficient permissions to view this page"?
(0) 讚! | 访儿小可爱

作者: 访儿小可爱


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-19 23:44:25 評論於
Can I submit my application now? It shows that I do not have the permission
(0) 讚! | 访儿小可爱

作者: 访儿小可爱


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-18 21:18:38 評論於
Have you encountered the message that you do not have permission to access the submission page? Why don't you have permission?
(0) 讚! | 访儿小可爱

作者: 般若沛旋


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-10 23:43:01 評論於
Any news about your paper? Mine was reviewed and finished on October 2nd. Now just waiting for the decision from the editor, who seems to be doing nothing
(0) 讚! | 般若沛旋

作者: 雨巷少年印枝


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-22 15:16:17 評論於
How did you handle it later and how can we speed it up?
(0) 讚! | 雨巷少年印枝

作者: 天霜天罡


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-20 16:51:51 評論於
Please translate the following paragraph into English and Japanese, with ":" and ":" as the titles: 7.29
(0) 讚! | 天霜天罡

作者: 般若沛旋


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-16 20:14:19 評論於
On which date did you submit your application? Mine was on July 21st, and I'm still waiting for a response from the editor
(0) 讚! | 般若沛旋

作者: 天霜天罡


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-14 11:31:04 評論於
The status has finally changed, 11 Reviewer(s) invited
(0) 讚! | 天霜天罡

作者: 天霜天罡


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-05 23:18:27 評論於
It has been 35 days since I was appointed as editor ?
(0) 讚! | 天霜天罡

作者: 般若沛旋


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-05 21:07:30 評論於
Have you sent the reminder letter?
(0) 讚! | 般若沛旋

作者: 天霜天罡


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-05 09:25:38 評論於
Wrote but no reply. This magazine is really slow, would rather be instantly rejected, waiting is torture
(0) 讚! | 天霜天罡

首頁    上一頁    1    2    3    4    5    6    下一頁    末頁  (頁
/6)

開始撰寫 [CANCER IMMUNOLOGY IMMUNOTHERAPY] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*